Business Wire

I-CARE

15.2.2024 14:31:33 CET | Business Wire | Press release

Share
I-care Launches the Wi-care 130 G23, a 100% Belgian High-precision Vibration Sensor With 3 Times More Powerful Data Flow

I-care, world leader in machine health, today presented the latest innovation in its Wi-care product range, the Wi-care 130 G23. This is the very first high-precision vibration sensor manufactured entirely in Belgium, capable of predicting more and more industrial breakdowns at an ever earlier stage. It is 100% autonomous, and therefore wireless, with a data flow that is 3 times more powerful and a battery life of 5 years. Thanks to this new technological innovation, I-care is strengthening AI-powered industrial maintenance 4.0. and enabling industries around the world to be more productive, safer and more sustainable.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215735570/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Wi-care 130 G23 (Photo: I-care)

The Wi-care 130 G23, the very first sensor to be manufactured entirely in Belgium, is a revolution in the predictive maintenance business. It is an innovative tool capable of carrying out 3 types of measurement on machines simultaneously: vibration analysis, shock identification and temperature monitoring. It incorporates the state-of-the-art technologies, in particular piezoelectric sensors, and works on all types of industrial machine.

The Wi-care 130 G23 is 100% autonomous, and therefore wireless. It has a battery that will last for more than 5 years of uninterrupted use, even when taking high-precision measurements that consume a lot of energy. The sensor is ATEX certified, with a data stream 3 times more powerful, offering high resolution and high frequency.

Like all products in the Wi-care range, this new sensor from I-care is fully integrated into the WaaS (Wi-care as a Service) ecosystem, an all-inclusive machine maintenance solution covering everything from hardware to support services via the iSee platform, including analysis and reporting. .

I-care is an expert in analysing machine vibrations to predict industrial failures months or even years before they occur. The Wi-care 130 G23 enables errors to be detected at an early stage, so that more and more industrial failures can be predicted earlier and earlier. In this way, I-care is delivering on its mission to "change the way the world works" by making industries around the world more efficient, safer and more environmentally friendly.

"With the Wi-care 130 G23, not only the design but also, and above all, the performance of Wi-care has been enormously improved. It's a real revolution, and 100% Belgian," says Fabrice Brion, CEO of I-care. "Above all, it's about enabling the industrial manufacturing companies to work better. At I-care, this is our way of contributing to a more efficient and sustainable economy.”

About I-care
The I-care Group is a world leader in machine health. Our mission is to change the way the world works. Our AI and data-driven solutions predict industrial failures months or even years before they occur. Thanks to I-care, machines around the world are safer, more productive and more sustainable. Founded in 2004 in Mons, Belgium, we employ over 800 people, with 36 offices in 16 countries (Asia-Pacific, EMEA and the US) and customers in over 55 countries.

Pictures Wi-care 130 G23

Please find the pictures of the Wi-care 130 G23 here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240215735570/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release

First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode

Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release

Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L

2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release

“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release

Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies

FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 13:00:00 CEST | Press release

Partnership includes FIFA tournaments and events from 2031Agreement encompasses both physical and digital collectibles, and for the first time brings the player jersey patch program to international footballPre-match press conferences for the FIFA World Cup Final to take place at Fanatics Fest on Friday, 17 July 2026 In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football tradin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye